{"id":"prevenar-13-single-dose","safety":{"commonSideEffects":[{"rate":"null","effect":"Pain, redness, or swelling at the injection site"},{"rate":"null","effect":"Fever"}]},"_chembl":{"chemblId":"CHEMBL2074774","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This is achieved through the administration of a polysaccharide conjugate vaccine, which contains 13 serotypes of Streptococcus pneumoniae. The vaccine works by inducing the production of antibodies that recognize and bind to the surface antigens of the bacteria, thereby preventing infection.","oneSentence":"Prevenar 13 stimulates the body's immune system to produce antibodies against Streptococcus pneumoniae.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:30:02.341Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive disease caused by Streptococcus pneumoniae in infants and young children"}]},"trialDetails":[{"nctId":"NCT07019909","phase":"PHASE1","title":"A Study to Learn About How Safe and Effective is 20vPnC and 13vPnC Vaccines in Chinese Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2025-07-06","conditions":"Pneumococcal Disease","enrollment":400},{"nctId":"NCT03942328","phase":"PHASE1, PHASE2","title":"Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2019-09-19","conditions":"Stage III Hepatocellular Carcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8","enrollment":85},{"nctId":"NCT06397768","phase":"PHASE3","title":"Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-05-13","conditions":"RSV Immunization","enrollment":2226},{"nctId":"NCT07286370","phase":"PHASE2","title":"A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-02-16","conditions":"Salmonella Infections","enrollment":537},{"nctId":"NCT05794230","phase":"PHASE3","title":"Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-03-27","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":1528},{"nctId":"NCT07333352","phase":"PHASE2","title":"PCV24 Clinical Trial in Infants and Young Children Aged 2 Months (Minimum 6 Weeks) to 71 Months","status":"RECRUITING","sponsor":"Shanghai Reinovax Biologics Co.,LTD","startDate":"2025-09-11","conditions":"Pneumococcal Infectious Disease","enrollment":480},{"nctId":"NCT06806137","phase":"PHASE3","title":"A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-05-15","conditions":"Chickenpox","enrollment":600},{"nctId":"NCT06855160","phase":"PHASE3","title":"A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-04-17","conditions":"Chickenpox","enrollment":900},{"nctId":"NCT03069703","phase":"PHASE2","title":"Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-02-05","conditions":"Invasive Pneumococcal Infection","enrollment":96},{"nctId":"NCT04429295","phase":"PHASE3","title":"Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-06-28","conditions":"Pertussis Immunisation, Diphtheria Immunisation, Polio Immunisation","enrollment":460},{"nctId":"NCT03104075","phase":"PHASE4","title":"Genomics and Epigenomics of the Elderly Response to Pneumococcal Vaccines","status":"COMPLETED","sponsor":"The Jackson Laboratory","startDate":"2017-04-17","conditions":"Pneumonia, Aging","enrollment":40},{"nctId":"NCT03819049","phase":"PHASE1, PHASE2","title":"A Study of Three Different Doses of VAC52416 (ExPEC10V) in Adults Aged 60 to 85 Years in Stable Health","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-06-06","conditions":"Extraintestinal Pathogenic Escherichia Coli Prevention","enrollment":836},{"nctId":"NCT01527591","phase":"NA","title":"Pneumococcal Conjugate Vaccine 13 (Prevnar13®) in Children Who Are Solid Organ Transplant Recipients (SOT)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2012-02-01","conditions":"Infection in Solid Organ Transplant Recipients","enrollment":17},{"nctId":"NCT06740630","phase":"PHASE3","title":"A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-01-10","conditions":"Chickenpox","enrollment":1840},{"nctId":"NCT03547271","phase":"PHASE3","title":"Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-12-14","conditions":"Meningococcal Infections","enrollment":1660},{"nctId":"NCT06703203","phase":"PHASE1, PHASE2","title":"Phase I/II Clinical Trial of 26-valent Pneumococcal Conjugate Vaccine","status":"ENROLLING_BY_INVITATION","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2024-08-27","conditions":"Pneumococcal Vaccines","enrollment":450},{"nctId":"NCT06693895","phase":"PHASE3","title":"A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-11-26","conditions":"Chickenpox","enrollment":750},{"nctId":"NCT03848065","phase":"PHASE1","title":"Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-028)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-04-02","conditions":"Pneumococcal Infections","enrollment":133},{"nctId":"NCT03574389","phase":"PHASE3","title":"A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Infants and Young Children","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-06-23","conditions":"Pneumococcal Infections, Pneumococcal Conjugate Vaccine","enrollment":936},{"nctId":"NCT04633226","phase":"PHASE3","title":"Safety and Immunogenicity of V114 in Healthy Infants in South Korea (V114-036)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-02-10","conditions":"Pneumococcal Disease","enrollment":58},{"nctId":"NCT04535037","phase":"PHASE4","title":"A Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK)'s Infanrix Hexa Vaccine (DTPa-HBV-IPV/Hib) Versus MCM Vaccine BV's Vaxelis Vaccine (DTaP5-HBV-IPV-Hib) in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-05-26","conditions":"Diphtheria","enrollment":500},{"nctId":"NCT05934890","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Immunogenicity and Safety of Walvax's PCV13-TT as Compared to Pfizer's PCV13","status":"ACTIVE_NOT_RECRUITING","sponsor":"Walvax Biotechnology Co., Ltd.","startDate":"2023-11-23","conditions":"Pneumococcal Disease, Invasive","enrollment":630},{"nctId":"NCT05329259","phase":"PHASE4","title":"A Study to Describe the Safety of a Vaccine (Called 13vPnC) in Healthy People 18 to 49 Years of Age in India","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-10-06","conditions":"Pneumococcal Disease","enrollment":200},{"nctId":"NCT03803202","phase":"PHASE1, PHASE2","title":"A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-01-24","conditions":"Pneumonia, Bacterial, Healthy Volunteers, Pneumococcal Disease","enrollment":630},{"nctId":"NCT03565900","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-09-12","conditions":"Pneumococcal Infections","enrollment":277},{"nctId":"NCT03692871","phase":"PHASE3","title":"A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-12-14","conditions":"Pneumococcal Infections","enrollment":2409},{"nctId":"NCT04384107","phase":"PHASE3","title":"Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-033)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-07-01","conditions":"Pneumococcal Infections","enrollment":694},{"nctId":"NCT04031846","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-09-04","conditions":"Pneumococcal Infections","enrollment":1184},{"nctId":"NCT03921424","phase":"PHASE3","title":"Safety and Immunogenicity of V114 in Children Infected With Human Immunodeficiency Virus (HIV) (V114-030/PNEU-WAY PED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-11-05","conditions":"Pneumococcal Infections","enrollment":407},{"nctId":"NCT04016714","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-08-28","conditions":"Pneumococcal Infections","enrollment":1191},{"nctId":"NCT03620162","phase":"PHASE3","title":"A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-18","conditions":"Pneumococcal Infections","enrollment":900},{"nctId":"NCT03885934","phase":"PHASE3","title":"Safety and Immunogenicity of Catch-up Vaccination Regimens of V114 (V114-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-06-25","conditions":"Pneumococcal Infections","enrollment":606},{"nctId":"NCT03873727","phase":"PHASE2","title":"Revaccination With PPS23 Boosted or Not by PCV13 in Splenectomised Patients.","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-08-27","conditions":"Splenectomised Patients","enrollment":39},{"nctId":"NCT02274415","phase":"PHASE2","title":"Immunogenicity Study of an Anti-pneumococcal Vaccination Strategy in Patients With Sickle Cells Disease","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2013-09-16","conditions":"Invasive Pneumococcal Infections, Sickle Cells Disease","enrollment":116},{"nctId":"NCT02049138","phase":"PHASE2","title":"An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitinib (ABT-494) in Adults With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-01-24","conditions":"Rheumatoid Arthritis","enrollment":493},{"nctId":"NCT02447718","phase":"PHASE4","title":"Vaccinating Children After Chemotherapy","status":"COMPLETED","sponsor":"Canadian Immunization Research Network","startDate":"2015-11-16","conditions":"Acute Lymphoblastic Leukemia","enrollment":156},{"nctId":"NCT04525599","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability and Immunogenicity of ASP3772, a Pneumococcal Vaccine, in Toddlers 12 to 15 Months of Age in Comparison to an Active Comparator","status":"COMPLETED","sponsor":"Affinivax, Inc.","startDate":"2020-09-22","conditions":"Healthy Volunteers, Pneumococcal Disease","enrollment":75},{"nctId":"NCT03480802","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-07-06","conditions":"Pneumococcal Infections","enrollment":302},{"nctId":"NCT03896477","phase":"PHASE3","title":"Study of 10-valent Pneumococcal Conjugate Vaccine (Pneumosil) Administered in a 2+1 Schedule to Healthy Infants","status":"COMPLETED","sponsor":"PATH","startDate":"2019-07-18","conditions":"Pneumonia, Pneumococcal","enrollment":660},{"nctId":"NCT03205371","phase":"PHASE3","title":"Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-11-07","conditions":"Meningitis, Meningococcal","enrollment":1183},{"nctId":"NCT03550313","phase":"PHASE2","title":"Study to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine Given With Prevnar 13 in Healthy Infants","status":"TERMINATED","sponsor":"Pfizer","startDate":"2018-06-01","conditions":"Pneumococcal Infections","enrollment":565},{"nctId":"NCT00853749","phase":"PHASE3","title":"Immune Response In Children Revaccinated With Pneumococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2009-05-05","conditions":"Invasive Pneumococcal Disease","enrollment":89},{"nctId":"NCT03480763","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-06-22","conditions":"Pneumococcal Infections","enrollment":652},{"nctId":"NCT04830358","phase":"PHASE1","title":"Safety and Immunogenicity of the 'EuPCV15' in Healthy Korean Adults","status":"COMPLETED","sponsor":"EuBiologics Co.,Ltd","startDate":"2020-05-28","conditions":"Pneumococcal Disease","enrollment":60},{"nctId":"NCT03731182","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children With Sickle Cell Disease (V114-023/PNEU-SICKLE)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-01-23","conditions":"Pneumococcal Infections","enrollment":104},{"nctId":"NCT04875819","phase":"PHASE4","title":"Safety and Immunogenicity Following Meningococcal and Pneumococcal Immunization Among Adult People Living With HIV","status":"RECRUITING","sponsor":"Thomas Benfield","startDate":"2021-04-28","conditions":"Hiv, Meningococcal Infections, Pneumococcal Infections","enrollment":55},{"nctId":"NCT03950622","phase":"PHASE3","title":"Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-06-13","conditions":"Pneumococcal Infections","enrollment":1205},{"nctId":"NCT03950856","phase":"PHASE3","title":"Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-06-12","conditions":"Pneumococcal Infections, Pneumonia, Pneumococcal","enrollment":2340},{"nctId":"NCT01641133","phase":"PHASE3","title":"Primary Vaccination With Either Synflorix™ or Prevenar 13™ or Both Vaccines and Booster Vaccination With Synflorix™","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-09-04","conditions":"Infections, Streptococcal, Streptococcus Pneumoniae Vaccines","enrollment":457},{"nctId":"NCT03547167","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-07-16","conditions":"Pneumococcal Infections","enrollment":1515},{"nctId":"NCT01896596","phase":"PHASE4","title":"Hepatitis B Vaccination in Infants","status":"COMPLETED","sponsor":"Public Health England","startDate":"2013-07","conditions":"Meningococcal Disease, Pneumococcal Disease, Haemophilus Influenzae Serotype b Disease","enrollment":300},{"nctId":"NCT04551248","phase":"","title":"Post-marketing Safety Evaluation of Pneumococcal Vaccines Among Children and Elderly Adults.","status":"UNKNOWN","sponsor":"Sungkyunkwan University","startDate":"2021-08-01","conditions":"Pneumococcal Vaccine Adverse Reaction","enrollment":1000000},{"nctId":"NCT01453998","phase":"PHASE2","title":"Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-10-14","conditions":"Acellular Pertussis, Hepatitis B, Haemophilus Influenzae Type b","enrollment":657},{"nctId":"NCT02494999","phase":"PHASE3","title":"A Phase III Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2016-06","conditions":"Pneumonia","enrollment":1200},{"nctId":"NCT04357522","phase":"PHASE3","title":"Immunogenicity and Safety Study of 15-Valent Pneumococcal Conjugate Vaccine in 2-month-old and 3-month-old Healthy Volunteers","status":"NOT_YET_RECRUITING","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2020-07","conditions":"Pneumonia, Pneumococcal","enrollment":1950},{"nctId":"NCT03777865","phase":"PHASE4","title":"Study To Describe The Safety Of 13-valent Pneumococcal Conjugate Vaccine In Children 6 To 17 Years Of Age In India","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-12-14","conditions":"Vaccines","enrollment":100},{"nctId":"NCT01735084","phase":"PHASE4","title":"Using Pneumococcal Vaccines in Combination for Maximum Protection From Ear and Lung Infections in First 3 Years of Life","status":"COMPLETED","sponsor":"Menzies School of Health Research","startDate":"2013-03-12","conditions":"Otitis Media, Febrile Illness, Cough","enrollment":261},{"nctId":"NCT03571607","phase":"PHASE3","title":"A Safety And Immunogenicity Study Of A 13-valent Pneumococcal Conjugate Vaccine In Japanese Subjects Aged 6 To 64 Years.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-07-12","conditions":"Pneumococcal Infections","enrollment":206},{"nctId":"NCT02853929","phase":"PHASE4","title":"Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-09-19","conditions":"Diphtheria, Hepatitis B, Acellular Pertussis","enrollment":551},{"nctId":"NCT03056924","phase":"","title":"Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab","status":"COMPLETED","sponsor":"Boston Medical Center","startDate":"2017-07-05","conditions":"Inflammatory Bowel Diseases","enrollment":173},{"nctId":"NCT02918708","phase":"PHASE4","title":"Assessment of Novel Pneumococcal Conjugate Vaccination Scheduled in UK Infants","status":"WITHDRAWN","sponsor":"Public Health England","startDate":"","conditions":"Vaccination, Immunization","enrollment":""},{"nctId":"NCT02573181","phase":"PHASE2","title":"Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in PPSV23-vaccinated Healthy Adults ≥65 Years of Age (V114-007)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-10-30","conditions":"Pneumococcal Infections","enrollment":253},{"nctId":"NCT02712177","phase":"","title":"Bexsero™and Routine Infant Vaccines: Effect of Coadministration on the Safety of Immunization","status":"COMPLETED","sponsor":"CHU de Quebec-Universite Laval","startDate":"2008-08","conditions":"Meningococcal Infections","enrollment":4535},{"nctId":"NCT02308540","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants","status":"COMPLETED","sponsor":"PATH","startDate":"2015-01-12","conditions":"Pneumococcal Disease","enrollment":346},{"nctId":"NCT02422264","phase":"PHASE4","title":"Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-01-22","conditions":"Acellular Pertussis, Tetanus, Poliomyelitis","enrollment":601},{"nctId":"NCT02037984","phase":"PHASE1, PHASE2","title":"Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-004)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-01-28","conditions":"Streptococcus Pneumoniae Infection, Pneumococcal Infections","enrollment":341},{"nctId":"NCT01262872","phase":"PHASE2","title":"Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety & Immunogenicity in Children & Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-02-09","conditions":"Infections, Streptococcal","enrollment":1320},{"nctId":"NCT02547649","phase":"PHASE2","title":"Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-10-08","conditions":"Pneumococcal Infections","enrollment":690},{"nctId":"NCT02531373","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-09-15","conditions":"Pneumococcal Infections","enrollment":338},{"nctId":"NCT01553279","phase":"PHASE3","title":"Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2012-03-30","conditions":"Neisseria Meningitidis, Bacterial Infections, Virus Diseases","enrollment":284},{"nctId":"NCT01215175","phase":"PHASE1","title":"Safety and Tolerability Study for the Pneumococcal Conjugate Vaccine V114 Versus Prevnar™ (V114-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-09-25","conditions":"Pneumococcal Infections","enrollment":150},{"nctId":"NCT01839188","phase":"PHASE3","title":"Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2013-05-01","conditions":"Neisseria Meningitidis, Bacterial Infections, Virus Diseases","enrollment":385},{"nctId":"NCT01513551","phase":"PHASE2","title":"The Safety, Tolerability, and Immunogenicity Profiles of a Single Dose of V114, PNEUMOVAX® 23, or PREVNAR 13® in Adults 50 Years of Age or Older (V114-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-03-13","conditions":"Pneumococcal Infections","enrollment":692},{"nctId":"NCT01174849","phase":"PHASE4","title":"Pneumococcal Vaccines Early and in Combination","status":"COMPLETED","sponsor":"Menzies School of Health Research","startDate":"2011-08","conditions":"Otitis Media","enrollment":425},{"nctId":"NCT01531322","phase":"PHASE1","title":"A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-10","conditions":"Pneumococcal Infection","enrollment":72},{"nctId":"NCT01000974","phase":"PHASE3","title":"Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-06-18","conditions":"Haemophilus Influenzae Type b","enrollment":4003},{"nctId":"NCT03552445","phase":"PHASE4","title":"Immunogenicity and Safety of a Tetanus-diphtheria Vaccine and a 13-valent Pneumococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"Korea University Guro Hospital","startDate":"2013-11-01","conditions":"Tetanus, Diphtheria, Pneumococcal Infections","enrollment":462},{"nctId":"NCT03405805","phase":"","title":"Immunological Memory Against Pneumococcus Induced by 3 Infant PCV 13 Vaccination Schedules","status":"UNKNOWN","sponsor":"Aghia Sophia Children's Hospital of Athens","startDate":"2016-12-12","conditions":"Immunogenicity, Vaccine, Immunologic Memory","enrollment":60},{"nctId":"NCT01939522","phase":"PHASE4","title":"Protection Against Pneumococcal Infection in Children With T1DM","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2013-08","conditions":"Type 1 Diabetes Mellitus","enrollment":50},{"nctId":"NCT01577771","phase":"PHASE4","title":"Immunogenicity and Reactogenicity of PCV13 Among Infants and Children in Burkina Faso","status":"COMPLETED","sponsor":"Agence de Médecine Préventive, France","startDate":"2013-02","conditions":"Pneumococcal Infections","enrollment":663},{"nctId":"NCT02357823","phase":"","title":"Antibodies and Memory Cells Role After Different Pneumococcal Vaccines in HIV Adults","status":"WITHDRAWN","sponsor":"University of Siena","startDate":"2015-01","conditions":"HIV, Pneumococcal Infections","enrollment":""},{"nctId":"NCT00345683","phase":"PHASE3","title":"Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-07","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":4021},{"nctId":"NCT02034877","phase":"PHASE4","title":"13-valent Pneumococcal Conjugate Vaccine Study in Adults and Children in India","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-08","conditions":"Prevention of Pneumonia and Invasive Disease Caused by the Serotypes in 13vPnC","enrollment":1200},{"nctId":"NCT00381615","phase":"PHASE2","title":"Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2006-09","conditions":"Healthy","enrollment":147},{"nctId":"NCT01218451","phase":"PHASE3","title":"NeisVac-C Single Prime Study in Infants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-09","conditions":"Neisseria Meningitidis","enrollment":956},{"nctId":"NCT02215863","phase":"PHASE4","title":"Immunogenicity and Safety of PCV13 and Fluad in Adults Aged ≥60 Years","status":"COMPLETED","sponsor":"Korea University Guro Hospital","startDate":"2014-09","conditions":"Influenza, Streptococcus Pneumoniae","enrollment":1195},{"nctId":"NCT01964716","phase":"PHASE3","title":"13vPnC Multidose Vial Safety, Tolerability and Immunogenicity Study in Healthy Infants.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-01","conditions":"Pneumococcal Vaccines","enrollment":500},{"nctId":"NCT02141009","phase":"PHASE4","title":"Community Acquired Pneumonia: Outcome, Quality of Life and Immune Status","status":"COMPLETED","sponsor":"St. Antonius Hospital","startDate":"2014-04","conditions":"Pneumonia, Streptococcus Pneumoniae, Immune Response","enrollment":60},{"nctId":"NCT00962780","phase":"PHASE3","title":"Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in HIV-Infected Subjects 6 Years of Age or Older Who Are Naive to Pneumococcal Vaccine","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-03","conditions":"HIV Infections, Pneumococcal Infections","enrollment":303},{"nctId":"NCT00488683","phase":"PHASE2","title":"B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-07","conditions":"Meningococcal Disease","enrollment":216},{"nctId":"NCT00918580","phase":"PHASE3","title":"Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Children With Sickle Cell Disease","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-11","conditions":"Pneumococcal Conjugate Vaccine","enrollment":158},{"nctId":"NCT01437267","phase":"PHASE2","title":"Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Children, Older Infants and Infants","status":"COMPLETED","sponsor":"Novartis","startDate":"2011-10","conditions":"Typhoid Fever","enrollment":120},{"nctId":"NCT01732198","phase":"PHASE2","title":"A Phase 2, Multicenter, Open-label Study to Assess the Immunogenicity of an Investigational Hib Vaccine (NU300)in Toddlers","status":"UNKNOWN","sponsor":"Nuron Biotech Inc.","startDate":"2013-03","conditions":"Infectious Disease","enrollment":220},{"nctId":"NCT01646398","phase":"PHASE3","title":"A Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Japanese Elderly Adults Aged 65 Years Old and Older","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-06","conditions":"Pneumococcal Vaccines, Pneumococcal Conjugate Vaccine","enrollment":764},{"nctId":"NCT00963235","phase":"PHASE3","title":"Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-11","conditions":"HIV Infections, Pneumococcal Infections","enrollment":331},{"nctId":"NCT00366899","phase":"PHASE3","title":"Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2006-10","conditions":"Vaccines, Pneumococcal","enrollment":605},{"nctId":"NCT00373958","phase":"PHASE3","title":"Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-09","conditions":"Vaccines, Pneumococcal","enrollment":666},{"nctId":"NCT01432262","phase":"PHASE3","title":"13-valent Pneumococcal Conjugate Vaccine Study in Adults => 50 Years of Age in Mexico","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-07","conditions":"Pneumococcal Infections","enrollment":324},{"nctId":"NCT00384059","phase":"PHASE3","title":"Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2006-10","conditions":"Vaccines, Pneumococcal","enrollment":286},{"nctId":"NCT00366678","phase":"PHASE3","title":"Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2006-10","conditions":"Vaccines, Pneumococcal","enrollment":613}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":53,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Prevenar 13 (Single Dose)","genericName":"Prevenar 13 (Single Dose)","companyName":"GlaxoSmithKline","companyId":"glaxosmithkline","modality":"Biologic","firstApprovalDate":"","aiSummary":"Prevenar 13 stimulates the body's immune system to produce antibodies against Streptococcus pneumoniae. Used for Prevention of invasive disease caused by Streptococcus pneumoniae in infants and young children.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}